The Securities and Exchange Commission on Tuesday amended its complaint against Richard Lee, a former portfolio manager at SAC Capital Advisors who the agency charged on July 25 with insider trading, to additionally charge Sandeep Aggarwal, the tipper of confidential information to Lee.
The SEC says that Aggarwal, a sell-side analyst, tipped Lee in advance of a July 2009 public announcement about an Internet search engine partnership between Microsoft and Yahoo.
Lee purchased large amounts of Yahoo stock in the SAC Capital hedge fund that he managed as well as in his personal trading account on the basis of the inside information.
In a parallel action, the U.S. Attorney’s Office for the Southern District of New York on Tuesday announced criminal charges against Aggarwal, who lives in India but recently returned to the U.S.
Sanjay Wadhwa, senior associate director of the SEC’s New York Regional Office, said in a statement that “Rather than rely on legitimate research methods, Aggarwal obtained confidential information from a close friend at Microsoft and passed it along to Lee knowing that he would likely trade on it.”
Top 10 Oil Companies To Own For 2015: VirnetX Holding Corp(VHC)
VirnetX Holding Corporation engages in developing and commercializing software and technology solutions for securing real-time communications over the Internet. Its software and technology solutions, which include secure domain name registry and GABRIEL Connection Technology, facilitate secure communications and create a secure environment for real-time communication applications, such as instant messaging, voice over Internet protocol, smart phones, eReaders, and video conferencing. The company focuses on commercializing its technology to original equipment manufacturers within the IP-telephony, mobility, fixed-mobile convergence, and unified communications markets. VirnetX Holding Corporation was founded in 2005 and is headquartered in Scotts Valley, California.
Advisors' Opinion:- [By Tom Shaughnessy]
The VirnetX (VHC) short side has opened its toolbox unveiling a simple and manipulative tool idea. It has been suggested that the United States Patent and Trademark Office ("USPTO") has a limitless amount of control over Federal Court decisions. Although the USPTO does have a bearing in the validity of patents, they in no way can nullify the decision of a Federal Court judge. New Bay Capital LLC ("New Bay") is utilizing inter partes reviews through the USTPO, although a Federal Court judge is not bound by the USTPO's findings.
- [By James E. Brumley]
While there's no denying that Vringo, Inc. (NASDAQ:VRNG) and VirnetX Holding Corporation (NYSEMKT:VHC) have made a big name for themselves - not to mention made big, even if uneven, gains for shareholder of VHC and VRNG - within the worked of intellectual property enforcement, bigger isn't always better. Smaller companies in the IP arena have a focus and flexibility that larger players like VirnetX and Vringo could never enjoy. Take, for instance, Endeavor IP Inc. (OTCBB:ENIP). This little patent owner may not look like much at first glance, but just ask the four organizations that have already entered licensing deals with ENIP and/or the four, well, now five companies that are currently litigating against Endeavor IP.... this little outfit packs a huge punch.
Hot Forestry Stocks To Invest In 2014: Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.
Inovio�� Solution
The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.
The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.
Cancer Synthetic Vaccines
The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.
Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.
Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).
In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.
Infectious Disease Synthetic Vaccines
In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.
Animal Health/Veterinary
VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.
The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.
Advisors' Opinion:- [By George Budwell]
Inovio Pharmaceuticals (NYSEMKT: INO ) develops DNA-based vaccines and delivers them using a proprietary electroporation technique. Shares of Inovio have been a roller coaster all year long, and have certainly been the playground of day traders. Last week, Inovio shares lost more than 10% of their value on heavy volume, suggesting the stock may continue to experience downward pressure. This rapid move downward is surprising because the company recently signed a licensing deal with Roche (NASDAQOTH: RHHBY ) to commercialize Inovio's multi-antigen DNA immunotherapies for prostate cancer and hepatitis B. As part of the deal, Inovio received $10 million upfront, and milestone payments could go as high as $412 million.
- [By Jake L'Ecuyer]
Inovio Pharmaceuticals (NYSE: INO) was also up, gaining 10.53 percent to $3.57 after the company received the ��est Theraputic Vaccine��award at the World Vaccine Congress after the close Wednesday.
- [By Sean Williams]
On the clinical data front, Alnylam Pharmaceuticals (NASDAQ: ALNY ) and Inovio Pharmaceuticals (NYSEMKT: INO ) both put investors in their happy place.
Hot Forestry Stocks To Invest In 2014: Nikon Corp (NINOY)
NIKON CORPORATION is a Japan-based company mainly engaged in the manufacture and sale of optical products. The Company is active in four business segments. The Precision Apparatus segment offers semiconductor exposure apparatus and liquid crystal (LC) exposure apparatus. The image segment provides digital cameras, film cameras and interchangeable lens. The Instruments segment offers microscopes, measuring machines and semiconductor inspection equipment. The Others segment provides glass materials, telescopes, glasses and survey airplanes.
As of August 19, 2009, the Company held a 92.17% stake in Metis NV. The Company has 65 subsidiaries and 10 associated companies in the country and overseas markets.
Advisors' Opinion:- [By Dan Carroll]
Unfortunately, the yen's impact on stocks has blurred the lines on investments. Look no further than down-on-its-luck camera maker Nikon (NASDAQOTH: NINOY ) . Nikon's shares gained more than 8% over the past week due to the yen's weakness, as the company rakes in more than a quarter of its sales in Europe. Still, the stock's lost more than 43% year to date.
Hot Forestry Stocks To Invest In 2014: Advance Auto Parts Inc(AAP)
Advance Auto Parts, Inc., through its subsidiaries, operates as a retailer of automotive aftermarket parts, accessories, batteries, and maintenance items. It operates in two segments, Advance Auto Parts (AAP) and Autopart International (AI). The AAP segment operates stores, which primarily offer auto parts, including alternators, batteries, chassis parts, clutches, engines and engine parts, radiators, starters, transmissions, and water pumps; accessories comprising floor mats, mirrors, vent shades, MP3 and cell phone accessories, and seat and steering wheel covers; chemicals consisting of antifreeze, freon, fuel additives, and car washes and waxes; and oil and other automotive petroleum products. This segment also provides battery and wiper installation, battery charging, check engine light reading, electrical system testing, video clinics and project brochures, loaner tool programs, and oil and battery recycling services; and sells its products through online. The AI segm ent operates stores that offer replacement parts for domestic and imported cars, and light trucks to customers in northeast and mid-Atlantic regions, as well as to warehouse distributors and jobbers in North America. As of January 1, 2011, the company operated 3,369 AAP stores, including 3,343 stores located in the northeastern, southeastern, and Midwestern regions of the United States under the Advance Auto Parts and Advance Discount Auto Parts trade names; 26 stores situated in Puerto Rico and the Virgin Islands under the Advance Auto Parts and Western Auto trade names; and 194 stores under the Autopart International trade name in the United States. It serves do-it-yourself, do-it-for-me, or commercial customers. The company was founded in 1929 and is based in Roanoke, Virginia.
Advisors' Opinion:- [By Dan Caplinger]
What's interesting, though, is that historically, auto-parts makers are seen as relying on the lack of success among automakers. After all, new cars don't need parts nearly as often as older cars do, and when Ford and GM perform well, their customers don't have to rely as much on Genuine Parts or competitors AutoZone (NYSE: AZO ) and Advance Auto Parts (NYSE: AAP ) for replacements. Yet, even though Advance's 15% gain, and AutoZone's 20% rise year to date, aren't quite as substantial as Genuine Parts, they still signal a paradigm shift in the way investors look at the industry, perhaps recognizing that for every new car sold, there's usually a used car that gets traded in, and so good news for Ford and GM sales might actually translate into more business for the parts industry.
- [By John Udovich]
Auto parts retailers like large cap O'Reilly Automotive Inc (NASDAQ: ORLY) and mid cap Advance Auto Parts, Inc (NYSE: AAP)�along with small cap auto parts stock Federal-Mogul Corp (NASDAQ: FDML) have been a bright spot on the economy as consumers try to stretch the lives of their automobiles or vehicles in the bad or uncertain economy. In fact, Investors Business Daily has recently noted that the�average age of cars on the road is about 11.5 years and that�� of course good news for auto parts retailers while�any uptick in sales or production of auto parts in general�will be good for companies like Federal-Mogul Corp. With that in mind, here�is a look at�how these three auto parts retailers or auto parts stocks are taking investors for a ride in a good way:
Hot Forestry Stocks To Invest In 2014: Powershares Etf Fund Trusts Ii (PGX)
The PowerShares Preferred Portfolio (Fund) is based on The BofA Merrill Lynch Core Fixed Rate Preferred Securities Index (Index). The Fund normally invest at least 90% of its total assets in securities that comprise the Index. The Index is designed to replicate the total return of a diversified group of investment-grade preferred securities. The Index is rebalanced on a monthly basis. The Fund seeks investment results that correspond generally to the price and yield (before fees and expenses) of a securities index. The Fund invests in sectors, such as basic materials, financial, utilities and unclassified. Invesco PowerShares Capital Management LLC. is the investment adviser. Advisors' Opinion:- [By Lawrence Meyers]
Public Storage has 10 different series of preferred stock, but I like the Series T because it trades at $21.83, which is more than 12% below par. I don�� see any reason for this discount, and it also boosts the 5.75% dividend (at par) to 6.58% at the current price.
Preferred Stocks to Buy: PowerShares Preferred Portfolio (PGX)
Dividend Yield: 6.6%
Hot Forestry Stocks To Invest In 2014: Forest Oil Corporation (FST)
Forest Oil Corporation, an independent oil and gas company, engages in the acquisition, exploration, development, and production of oil, natural gas, and natural gas liquids in the United States. The company primarily has interests in the properties in the Texas Panhandle; the east Texas/north Louisiana; and the Eagle Ford Shale in south Texas. As of December 31, 2011, its total estimated proved oil and gas reserves were approximately 1,904 billion cubic feet equivalent. The company was founded in 1916 and is headquartered in Denver, Colorado with an additional office in Houston, Texas.
Advisors' Opinion:- [By Paul Ausick]
Stocks on the Move: Potbelly Corp. (NASDAQ: PBPB) is up 119.1% at $30.68 after a blistering IPO at $14 a share. OCI Partners LP (NYSE: OCIP) is up 5.6% at $19.01 after an IPO at $18.00 a share. Cherry Hill Mortgage Investment Corp. (NYSE: CHMI) is down 7.6% at $18.48 following its IPO on Friday morning. Discovery Laboratories Inc. (NASDAQ: DSCO) is up 37.1% at $2.70 following approval of updated specifications for a drug to prevent respiratory distress in premature infants. Forest Oil Corp. (NYSE: FST) is down 9.7% at $5.74 following the sale of $1 billion worth of assets in the Texas panhandle.
- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Tuesday morning, the energy sector proved to be a source of strength for the market. Leading the sector was strength from Forest Oil (NYSE: FST) and Swift Energy Co (NYSE: SFY). Financial shares declined around 0.57 percent in Tuesday's trading. - [By Ben Levisohn]
It’s Christmas, a time when we wish for peace on earth and goodwill towards everyone. So, with investors in a forgiving mood, it might seem tempting to buy energy exploration & production companies that have underperformed in 2013–you know, Forest Oil (FST), Newfield Exploration (NFX) and the like.
- [By Ben Levisohn]
Forest Oil�(FST) has gained 7.2% to $6.81 after it announced the sale of some Texas assets for $1 billion.
Lannett Company (LCI) has dropped 12% to $18.41 after the generic drug maker announced a secondary stock offering.
Hot Forestry Stocks To Invest In 2014: Foster Wheeler AG. (FWLT)
Foster Wheeler AG, through its subsidiaries, operates as an engineering and construction contractor; and power generating equipment supplier worldwide. Its Global Engineering and Construction division designs, engineers, and constructs onshore and offshore upstream oil and gas processing facilities; natural gas liquefaction facilities and receiving terminals; gas-to-liquids facilities; and oil refining, chemical and petrochemical, pharmaceutical, and biotechnology facilities, as well as related infrastructure, including power generation, distribution, gasification, and processing facilities for metals and mining sector. This division also designs carbon capture and storage, and solid fuel-fired integrated gasification combined-cycle power plants, as well as coal-to-liquids, coal-to-chemicals, and biofuels facilities; and operates power generation facilities, such as conventional and renewable source, and waste-to-energy facilities. In addition, it offers project and constr uction management services, including procurement of equipment, materials, and services from third-party suppliers and contractors; provides environmental remediation services; and designs and supplies direct-fired furnaces comprising fired heaters and waste heat recovery generators used in refinery, chemical, petrochemical, and oil and gas processes. The company�s Global Power division designs, manufactures, and erects steam generators and auxiliary equipment, including surface condensers, feedwater heaters, coal pulverizers, steam generator coils and panels, biomass gasifiers, and replacement parts; nitrogen-oxide reduction systems and components; and flue gas desulfurization equipment for steam generators. It also offers various site services; conducts research and development in combustion, fluid and gas dynamics, heat transfer, materials, and solid mechanics areas; and licenses technology to other steam generator suppliers. The company was founded in 1894 and is based in Geneva, Switzerland.
Advisors' Opinion:- [By alicet236]
Foster Wheeler AG (FWLT): CEO and President Kent Masters sold 130,668 Shares
CEO and President of Foster Wheeler AG (FWLT) Kent Masters sold 130,668 shares on 06/05/2014 at an average price of $33.95. Foster Wheeler AG together with its subsidiaries, is a provider of construction and engineering services. Foster Wheeler Ag has a market cap of $3.44 billion; its shares were traded at around $34.45 with a P/E ratio of 34.00 and P/S ratio of 1.06. The dividend yield of Foster Wheeler Ag stocks is 1.20%.
- [By CRWE]
Foster Wheeler AG (Nasdaq:FWLT) reported that a subsidiary of its Global Engineering and Construction Group has been awarded a contract by PDVSA Petrč´¸leo S.A. for the engineering, procurement services and construction management (EPCm) for the El Palito Refinery Expansion Project in Venezuela.
No comments:
Post a Comment